HK1051504A1 - Use of compounds with 5-ht1a activity useful for treating disorders of the outer retina - Google Patents

Use of compounds with 5-ht1a activity useful for treating disorders of the outer retina

Info

Publication number
HK1051504A1
HK1051504A1 HK03103444A HK03103444A HK1051504A1 HK 1051504 A1 HK1051504 A1 HK 1051504A1 HK 03103444 A HK03103444 A HK 03103444A HK 03103444 A HK03103444 A HK 03103444A HK 1051504 A1 HK1051504 A1 HK 1051504A1
Authority
HK
Hong Kong
Prior art keywords
compounds
treating disorders
activity useful
outer retina
ht1a activity
Prior art date
Application number
HK03103444A
Other languages
English (en)
Inventor
Robert J Collier Jr
Michael A Kapin
Mark R Hellber
Thomas R Dean
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of HK1051504A1 publication Critical patent/HK1051504A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Liquid Crystal Substances (AREA)
HK03103444A 2000-03-17 2003-05-15 Use of compounds with 5-ht1a activity useful for treating disorders of the outer retina HK1051504A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19027900P 2000-03-17 2000-03-17
PCT/US2001/005700 WO2001070222A2 (en) 2000-03-17 2001-02-23 Compounds with 5-ht1a activity useful for treating disorders of the outer retina

Publications (1)

Publication Number Publication Date
HK1051504A1 true HK1051504A1 (en) 2003-08-08

Family

ID=22700682

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03103444A HK1051504A1 (en) 2000-03-17 2003-05-15 Use of compounds with 5-ht1a activity useful for treating disorders of the outer retina

Country Status (19)

Country Link
EP (3) EP1263434A1 (xx)
JP (5) JP2003527423A (xx)
KR (3) KR20030016239A (xx)
CN (2) CN1418100A (xx)
AR (1) AR028258A1 (xx)
AT (1) ATE247507T1 (xx)
AU (5) AU2001238552A1 (xx)
BR (3) BR0109193A (xx)
CA (3) CA2400637A1 (xx)
DE (1) DE60100625T2 (xx)
DK (1) DK1263504T3 (xx)
ES (1) ES2204848T3 (xx)
HK (1) HK1051504A1 (xx)
MX (3) MXPA02009071A (xx)
PL (1) PL203709B1 (xx)
PT (1) PT1263504E (xx)
TW (1) TWI268777B (xx)
WO (3) WO2001070223A1 (xx)
ZA (1) ZA200206350B (xx)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763619B2 (en) 2000-03-17 2010-07-27 Alcon, Inc. Compounds with 5-HT1A activity useful for treating disorders of the outer retina

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
KR20030016239A (ko) * 2000-03-17 2003-02-26 알콘, 인코퍼레이티드 녹내장 치료용의 5-ｈｔ２ 및 5-ｈｔ１ａ 아고니스트활성을 지닌 화합물
TW593302B (en) * 2001-12-20 2004-06-21 Alcon Inc Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
MXPA05006277A (es) 2002-12-13 2005-09-08 Alcon Inc Analogos de benzopirano novedosos y su uso para el tratamiento de glaucoma.
JP2004262812A (ja) * 2003-02-28 2004-09-24 Rohto Pharmaceut Co Ltd 眼圧低下剤
CN100563648C (zh) * 2003-04-25 2009-12-02 田边三菱制药株式会社 包含亚烷基二氧苯衍生物的口服组合物
US7476687B2 (en) 2003-11-26 2009-01-13 Alcon, Inc. Substituted furo[2,3-g]indazoles for the treatment of glaucoma
AR046890A1 (es) 2003-12-15 2005-12-28 Alcon Inc [1,4] oxazino [2,3-g] indazoles sustituidos para el tratamiento del glaucoma.
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
EP1792629A4 (en) 2004-08-25 2010-08-25 Takeda Pharmaceutical PREVENTIVE / REMEDY AGENTS FOR INCONTINENCE OF STRESS AND SELECETING METHOD THEREOF
US7425572B2 (en) 2004-12-08 2008-09-16 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
EP2018863B9 (en) 2006-05-16 2015-02-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
WO2008024846A2 (en) * 2006-08-25 2008-02-28 Allergan, Inc. Brimonidine and timolol compositions
EP2896624B1 (en) 2007-03-28 2016-07-13 Atir Holding S.A. Heterotricyclic compounds as serotonergic and/or dopaminergic agents and uses thereof
US20100266504A1 (en) 2007-11-15 2010-10-21 Takahiro Matsumoto Condensed pyridine derivative and use thereof
TW201010727A (en) * 2008-09-03 2010-03-16 Alcon Res Ltd Pharmaceutical composition having relatively low ionic strength
KR101769637B1 (ko) 2009-11-09 2017-08-18 알러간, 인코포레이티드 모발 성장을 촉진하기 위한 조성물 및 방법
JPWO2011071136A1 (ja) 2009-12-11 2013-04-22 アステラス製薬株式会社 線維筋痛症治療剤
BR112015019546A2 (pt) 2013-02-15 2017-07-18 Allergan Inc implante de distribuição de drogas prolongado
JPWO2019131902A1 (ja) 2017-12-27 2020-12-10 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
CA3130767A1 (en) 2019-02-27 2020-09-03 The Regents Of The University Of California N-substituted indoles and other heterocycles for treating brain disorders
BR112021016620A2 (pt) 2019-02-27 2021-11-03 Univ California Azepino-indóis e outros heterociclos para o tratamento de distúrbios cerebrais
WO2023118544A1 (en) * 2021-12-23 2023-06-29 Cilcare Dev 4-phenyl-tetrahydropyridine derivatives for treating hearing diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02262518A (ja) * 1989-04-03 1990-10-25 Kaken Pharmaceut Co Ltd 眼圧調整剤
JP2824863B2 (ja) * 1989-07-12 1998-11-18 エーザイ株式会社 α▲下１▼―ブロッカー点眼剤
TW270114B (xx) * 1993-10-22 1996-02-11 Hoffmann La Roche
US5521183A (en) * 1994-08-30 1996-05-28 Allergan Use of 5-HT ligands as anti-pruritic agents
US5998467A (en) * 1995-10-25 1999-12-07 Mitsubishi Chemical Corporation Medicine for oculopathy
JP3958391B2 (ja) * 1995-10-25 2007-08-15 三菱化学株式会社 眼疾患用薬剤
WO1998018458A1 (en) * 1996-10-31 1998-05-07 Alcon Laboratories, Inc. Opthalmological compositions containing serotonin 5-ht1a receptor agonist and their use in the treatment of glaucoma
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
GB9819033D0 (en) * 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds VI
KR20030016239A (ko) * 2000-03-17 2003-02-26 알콘, 인코퍼레이티드 녹내장 치료용의 5-ｈｔ２ 및 5-ｈｔ１ａ 아고니스트활성을 지닌 화합물

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763619B2 (en) 2000-03-17 2010-07-27 Alcon, Inc. Compounds with 5-HT1A activity useful for treating disorders of the outer retina

Also Published As

Publication number Publication date
AR028258A1 (es) 2003-04-30
KR20020082885A (ko) 2002-10-31
MXPA02009072A (es) 2003-03-12
MXPA02009071A (es) 2003-05-23
CA2400637A1 (en) 2001-09-27
JP2011037901A (ja) 2011-02-24
CN1198605C (zh) 2005-04-27
ES2204848T3 (es) 2004-05-01
WO2001070222A3 (en) 2002-07-25
EP1267878A2 (en) 2003-01-02
CA2399985A1 (en) 2001-09-27
JP2003527423A (ja) 2003-09-16
AU2005202600B2 (en) 2008-07-31
JP4789231B2 (ja) 2011-10-12
MXPA02009073A (es) 2003-03-12
JP2003527422A (ja) 2003-09-16
DK1263504T3 (da) 2003-12-08
ATE247507T1 (de) 2003-09-15
CN1418121A (zh) 2003-05-14
CA2400639C (en) 2011-08-16
CA2400639A1 (en) 2001-09-27
WO2001070230A3 (en) 2002-04-25
PL358306A1 (en) 2004-08-09
KR100749191B1 (ko) 2007-08-13
CN1418100A (zh) 2003-05-14
AU2001238552A1 (en) 2001-10-03
BR0109211A (pt) 2003-02-11
BR0109230A (pt) 2003-06-03
PT1263504E (pt) 2003-12-31
AU4531001A (en) 2001-10-03
EP1263434A1 (en) 2002-12-11
DE60100625D1 (de) 2003-09-25
DE60100625T2 (de) 2004-02-26
WO2001070223A1 (en) 2001-09-27
AU2001245310B2 (en) 2005-03-17
AU2005202600A1 (en) 2005-07-07
WO2001070230A2 (en) 2001-09-27
KR20030016239A (ko) 2003-02-26
EP1263504B1 (en) 2003-08-20
AU2001239836A1 (en) 2001-10-03
JP2003527427A (ja) 2003-09-16
EP1263504A2 (en) 2002-12-11
KR20030009390A (ko) 2003-01-29
ZA200206350B (en) 2003-08-08
JP2011153158A (ja) 2011-08-11
TWI268777B (en) 2006-12-21
BR0109193A (pt) 2003-05-27
PL203709B1 (pl) 2009-11-30
WO2001070222A2 (en) 2001-09-27

Similar Documents

Publication Publication Date Title
HK1051504A1 (en) Use of compounds with 5-ht1a activity useful for treating disorders of the outer retina
IL160389A0 (en) Use of flibanserin for the treatment of sexual disorders
AU2003286567A8 (en) Methods for the treatment of skin disorders
PL366636A1 (en) Pyranoindazoles and their use for the treatment of glaucoma
AU2002218742A1 (en) Application of photochemotherapy for the treatment of cardiac arrhythmias
AU4256801A (en) Treatment of movement disorders
HK1053058A1 (zh) 普拉克索用於治療成癮性疾病的用途
IL153425A0 (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
AU6910600A (en) Methods for the treatment of mental disorders
PL368556A1 (en) Methods for treating or preventing skin disorders using cd2-binding agents
HUP0201791A2 (en) The use of escitalopram for treatment of neurotic disorders
IL157145A0 (en) Use of dc23 antagonists for the treatment of neoplastic disorders
EP1126850A4 (en) TREATMENT OF CONDITIONS OF THE RETINA
ZA200307475B (en) Carbamate compounds for use in the treatment of pain.
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
EP1461030A4 (en) AMINOALKYL-BENZOFURAN-5-OL COMPOUNDS FOR THE TREATMENT OF GLAUCOMA
HK1057332A1 (en) Use of 3-benzoylphenylacetic acid derivatives for the treatment of retinal disorders
HK1049122A1 (en) The use of mirtazapine for the treatment of sleep disorders
EP1455780A4 (en) NEW BENZODIFURANIMIDAZOLIN AND BENZOFURANIMIDAZOLIN DERIVATIVES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA
AU2001251306A1 (en) Treatment of sleep disorders with hypocretin-1
AU2003303217A8 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
MXPA03004190A (es) Tratamiento de trastornos de ansiedad.

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140223